The treatment of gynecological disorders and prostate cancer.
ORAL Menopausal hormone replacement therapy: Adult: In menopausal women: 10-20 mcg daily in conjunction w/ a progestogen in women w/ uterus. Female hypogonadism: Adult: 10-50 mcg daily in a cyclical regimen. As part of combined oral contraceptive: Adult: As the oestrogenic component of combined oral contraceptive: 20-40 mcg/ day.
Uterine, liver & mammary carcinoma, thromboembolic disorders. Pregnancy, lactation, untreated endometriosis, jaundice, undiagnosed vag bleeding. Asthma; epilepsy; migraine; DM; cardiac or renal dysfunction; hepatic disease; familial defects of lipoprotein metabolism. Increased risk of endometrial cancer in unopposed oestrogen therapy. Increased risk of gallbladder disease in women on postmenopausal oestrogens. Large doses may increase CV risk, BP, risk of thrombophlebitis & pulmonary embolism.
Oedema, hypertension; dizziness; headache; thromboembolism; cholestatic jaundice; nausea, vomiting; disturbance of menstrual cycle; fluid retention, discomfort in breast, wt gain/loss; increased appetite, increased tendency for vag candidiasis; mental depression; alteration In libido; rashes; alopoecia, hirsutism; gynaecomastia & Impotence. Endometrial cancer (prolonged use).
Use is contraindicated during pregnancy. Breastfeeding is not recommended during use of this drug.
.png&w=384&q=75)